Fulvestrant (Faslodex™) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials - Concepedia

Concepedia

Publication | Closed Access

Fulvestrant (Faslodex™) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials

69

Citations

6

References

2003

Year

L. Mauriac, John Pippen, J. Albano, S. Gertler, C. Kent Osborne

European Journal of Cancer

Second-line TreatmentNon-visceral MetastasesAdvanced Breast CancerSurgical OncologyBreast OncologyMedicineGynecologyBreast CancerCancer TreatmentOncologyRadiation Oncology

References

	Year	Citations

Page 1